Can Fite Biopharma Ltd (CANF) Earns Buy Rating from Roth Capital
Separately, Rodman & Renshaw began coverage on Can Fite Biopharma in a research note on Monday, August 29th. They issued a “buy” rating and a $6.00 price target on the stock.
Can Fite Biopharma (NASDAQ:CANF) opened at 2.45 on Wednesday. Can Fite Biopharma has a one year low of $1.85 and a one year high of $4.05. The stock’s 50 day moving average is $2.50 and its 200 day moving average is $2.56. The stock’s market capitalization is $34.85 million.
Can Fite Biopharma Company Profile
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.
Receive News & Stock Ratings for Can Fite Biopharma Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can Fite Biopharma Ltd and related stocks with our FREE daily email newsletter.